A Randomized Double-Blind Phase 2 Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+) Her2 Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 20 May 2016
At a glance
- Drugs Seribantumab (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 17 May 2016 Final analysis and extended subgroup analysis were presented at the AACR Precision Medicine Series, according to a Merrimack Pharmaceuticals media release.
- 17 May 2016 Results from the final analysis and extended subgroup analysis published in a Merrimack Pharmaceuticals media release.
- 11 Apr 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History